WHO approves Biological E's Encephalitis vaccine
BioE spokespersons said in a release that the WHO approval was a key step in enabling the vaccine to be distributed to developing countries by the GAVI Alliance. BioE based the vaccine off French biotech company Valneva's SE technology after BioE and Valneva entered into partnership in 2005, according to Business Standard.
The vaccine was already approved and marketed in India under the name JEEV. It is expected to be approved for pediatric use by the end of the year, Business Standard reports.
"It is an extremely important achievement for vaccines community as our vaccine's prequalification is well in time to support GAVI's plans of introducing the JE vaccine in many developing countries," BioE Managing Director Mahima Datla said, according to Business Standard.
BioE recently established a five-year supply agreement with the GAVI alliance. The agreement will combine BioE's pentavalent vaccine with GlaxoSmithKline's polio vaccine to create a six-in-one pediatric vaccine.
The GAVI Alliance is an organization that seeks to improve global health by supplying poor, developing nations with access to critical immunizations pertinent to good health.